The ingredients are used in EVA Pharma’s Carnivita Forte, an over-the-counter product for men who wish to increase sperm count and motility.
EVA Pharma has signed a multiyear supply agreement for two of Lonza’s (Basel, Switzerland) Carnipure L-carnitine products-Carnipure tartrate and Carnipure crystalline. The companies have also signed a Carnipure brand-licensing agreement.
The ingredients are used in EVA Pharma’s Carnivita Forte, an over-the-counter product for men who wish to increase sperm count and motility. Each tablet contains 1 g of Carnipure tartrate.
“Thanks to Lonza’s continuous support, we have been able to establish Carnivita Forte as one of our best-selling products in the field of urology,” said EVA Pharma’s CEO Riad Armanious.
Lonza says that L-carnitine plays an important role in fat and energy metabolism, helping to transport long-chain fatty acids into the cells’ mitochondria where they are transformed into energy. Organs and cells with high energy demands, such as sperm, contain high levels of L-carnitine upon which they depend for normal functionality.
“Extensive research shows that Carnipure supplementation may positively influence sperm quality or, more specifically, sperm count, sperm motility, and the number of motile sperm, thus playing an important part in male fertility,” says Lonza’s nutrition science team leader, Ulla Freitas.
Lonza is a leading producer of L-carnitine. Under the Carnipure name, the company offers Carnipure crystalline, which is pure L-carnitine, as well as Carnipure tartrate, a nonhygroscopic form comprising L-carnitine and tartaric acid.